In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are used in the collection, preparation, and examination of specimens taken from the human body. This includes Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers, Oncology and Reproductive Health Diagnostics. Breakpoint Cluster Region- Tyrosine-Protein Kinase ABL1 fusion gene (BCR-ABL) tests are carried out to detect fusion gene mutations in patient tissue samples; the outcome of which may guide therapies to treat various cancers including Chronic Myeloid Leukemia (CML), Acute Lymphoblastic Leukemia (ALL) and Acute Myelogenous Leukemia (AML). GlobalData uses proprietary data and analytics to provide a comprehensive report on the bcr-abl tests devices market, including market shares of different players within Austria. Buy the latest report here.
In 2023, GlobalData’s Market Model methodology determined that the leading player in the bcr-abl tests market in Austria was Abbott Laboratories followed by Bio-Techne, Sysmex, Bio-Rad Laboratories and Danaher.
BCR-ABL Tests include BCR-ABL In Situ Hybridisation Tests and BCR-ABL Nucleic Acid Amplification Tests (NAATs).
The value of the bcr-abl tests devices market within Austria was expected to be over $0.06m in 2023.
For the latest complete market share analysis of bcr-abl tests device market in Austria, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.